Organigram Global Inc. (NASDAQ:OGI) reported weaker second-quarter fiscal 2026 results as declining vape and infused pre-roll sales weighed on revenue and profitability. Though the Canadian cannabis producer said operational changes and its recent acquisition of Germany-based Sanity Group position the company for stronger performance in the second half of the year. • Organigram Global shares are sliding. Why are OGI shares down? Organigram Q2 Revenue Falls As Vape Sales And Margins Weaken The company reported a second-quarter loss of one cent, with sales of $43.59 million, missing the consensus of $52.06 million. Adjusted EBITDA fell 82% to $0.9 million. CEO James Yamanaka said the quarter reflected underperformance in vapes and temporary production issues in infused pre-rolls, alongside slower industry growth. "We acted quickly to address these ...Full story available on Benzinga.com

SNDL Inc (NASDAQ:SNDL) shares are trading lower on Wednesday afternoon after reporting first-quarter financial results that featured a revenue miss. Here’s what investors need to know. SNDL stock is among today’s weakest performers. What’s weighing on SNDL shares? SNDL Q1 Financial Performance and Segment Data The company posted a net loss of four cents per share, which was in line with analyst expectations, but its net revenue of $195.9 million fell short of the estimated $210.3 million. This performance represents a 4.4% revenue decrease from the same period in the prior year, a decline primarily driven by market headwinds impacting both the liquor and cannabis segments. The liquor retail division saw revenue slide 4.9% to $104.1 ...Full story available on Benzinga.com

Akanda Corp. (NASDAQ:AKAN) shares continued to surge today after U.S. regulators moved to reclassify certain marijuana products, fueling a broader rally in cannabis stocks. • Akanda stock is charging ahead with explosive momentum. What’s fueling AKAN momentum? Regulatory Action and Sector Impact The U.S. Department of Justice and Drug Enforcement Administration placed FDA-approved marijuana-based products and state-regulated medical marijuana under Schedule III, also launching an expedited process to consider broader reclassification from Schedule I. A new administrative hearing is scheduled for June 29, 2026, to accelerate the rulemaking process and provide clearer guidance for research and medical use. The move follows earlier speculation around potential reclassification, which lifted peers including Tilray Brand Ind  (NASDAQ:TLRY), Canopy Growth and Cronos. Akanda ...Full story available on Benzinga.com